Tatar O - Search Results

1

The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration.

Grisanti S, Tatar O. Grisanti S, et al. Among authors: tatar o. Prog Retin Eye Res. 2008 Jul;27(4):372-90. doi: 10.1016/j.preteyeres.2008.05.002. Epub 2008 Jul 14. Prog Retin Eye Res. 2008. PMID: 18621565 Review.

2

Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.

Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X; Tübingen Bevacizumab Study Group, Grisanti S. Zhu Q, et al. Among authors: tatar o. Ophthalmology. 2008 Oct;115(10):1750-5, 1755.e1. doi: 10.1016/j.ophtha.2008.04.023. Epub 2008 Aug 16. Ophthalmology. 2008. PMID: 18708261

3

Differential expression of vascular endothelial growth factor-a isoforms in neovascular age-related macular degeneration.

Grisanti S, Zhu Q, Tatar O, Lueke J, Lueke M, Tura A, Grisanti S. Grisanti S, et al. Among authors: tatar o. Retina. 2015 Apr;35(4):764-72. doi: 10.1097/IAE.0000000000000385. Retina. 2015. PMID: 25494018

4

Early effects of triamcinolone on vascular endothelial growth factor and endostatin in human choroidal neovascularization.

Tatar O, Shinoda K, Kaiserling E, Pertile G, Eckardt C, Mohr A, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Tatar O, et al. Arch Ophthalmol. 2008 Feb;126(2):193-9. doi: 10.1001/archophthalmol.2007.40. Arch Ophthalmol. 2008. PMID: 18268209

5

Expression of endostatin in human choroidal neovascular membranes secondary to age-related macular degeneration.

Tatar O, Shinoda K, Adam A, Rohrbach JM, Lucke K, Henke-Fahle S, Bartz-Schmidt KU, Grisanti S. Tatar O, et al. Exp Eye Res. 2006 Aug;83(2):329-38. doi: 10.1016/j.exer.2005.12.017. Epub 2006 Apr 11. Exp Eye Res. 2006. PMID: 16584730

6

Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes.

Tatar O, Kaiserling E, Adam A, Gelisken F, Shinoda K, Völker M, Lafaut BA, Bartz-Schmidt KU, Grisanti S. Tatar O, et al. Arch Ophthalmol. 2006 Jun;124(6):815-23. doi: 10.1001/archopht.124.6.815. Arch Ophthalmol. 2006. PMID: 16769835

7

Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization.

Tatar O, Adam A, Shinoda K, Kaiserling E, Boeyden V, Claes C, Eckardt C, Eckert T, Pertile G, Scharioth GB, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Tatar O, et al. Arch Ophthalmol. 2009 Mar;127(3):275-81. doi: 10.1001/archophthalmol.2008.602. Arch Ophthalmol. 2009. PMID: 19273790

8

Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.

Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P; Tübingen Bevacizumab Study Group. Yoeruek E, et al. Among authors: tatar o. Acta Ophthalmol. 2008 May;86(3):322-8. doi: 10.1111/j.1600-0420.2007.01049.x. Epub 2007 Nov 8. Acta Ophthalmol. 2008. PMID: 17995975

9

Safety profile of bevacizumab on cultured human corneal cells.

Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Yoeruek E, et al. Among authors: tatar o. Cornea. 2007 Sep;26(8):977-82. doi: 10.1097/ICO.0b013e3180de1d0a. Cornea. 2007. PMID: 17721300

10

Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients.

Ziemssen F, Lüke M, Messias A, Beutel J, Tatar O, Zrenner E, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Ziemssen F, et al. Among authors: tatar o. Int Ophthalmol. 2008 Apr;28(2):101-9. doi: 10.1007/s10792-007-9122-1. Epub 2007 Jul 20. Int Ophthalmol. 2008. PMID: 17634860

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results